<DOC>
	<DOCNO>NCT01454180</DOCNO>
	<brief_summary>The purpose study determine proportion patient alive 12 month begin trial patient advance pancreatic carcinoma individually select group accord expression tumor tissue therapeutic target .</brief_summary>
	<brief_title>Study Individualized Selection Chemotherapy Patients With Advanced Pancreatic Carcinoma According Therapeutic Targets</brief_title>
	<detailed_description>Phase II , open two branch , conventional treatment administer patient diagnose metastatic pancreatic carcinoma . Patients randomize ( 1:1 ) treatment arm control arm experimental treatment guide therapeutic target . Patients control treatment arm treat scheme use study accord discretion physician responsible . Patients analyze `` intention treat . '' In experimental treatment arm ( therapeutic target ) within 15 day determine marker therapeutic target detail protocol , either pre-existing tumor sample fresh sample obtain biopsy . Based result analysis , prescribe chemotherapy treatment determine possible treatment currently use pancreatic carcinoma , gemcitabine , gemcitabine capecitabine , gemcitabine erlotinib , FOLFIRINOX , FOLFOX , FOLFIRI . Treatment duration indefinite .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Histological cytological diagnosis pancreatic carcinoma . Patients &gt; 18 year . Measurable measurable disease . Life expectancy &gt; 3 month discretion investigator . Good general condition determine ECOG scale ( score 01 ) Candidate firstline systemic chemotherapy accord standard practice . Availability tumor tissue opportunity tumor biopsy determination biomarkers correlation treatment . Adequate hematologic function : ANC &gt; 1.5 x 103 / L , absolute count platelet &gt; 100 x 109 / L , normal value INR PTT . Adequate liver function : total serum bilirubin &lt; 2 mg / dL , ALT AST &lt; 3 time upper limit establish laboratory ( LSR ) &lt; 5 LSR patient liver metastasis . Adequate renal function : serum creatinine &lt; 1.5 LSR . Patients receive prior chemotherapy advance pancreatic carcinoma . Will result exclude patient previously receive adjuvant treatment gemcitabine fluoropyrimidines . Also exclude patient previously receive preoperative neoadjuvant treatment localize disease chemotherapy / radiotherapy . Patients contraindicated administration either drug use firstline treatment pancreatic cancer : Gemcitabine , 5'Fluouracilo , Leucovorin , Capecitabine , Oxaliplatin , Irinotecan , Erlotinib . Pregnant breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Therapeutic target Pancreas</keyword>
</DOC>